Türk Medline
ADR Yönetimi
ADR Yönetimi

SUCCESSFUL TREATMENT OF MUSK ANTIBODY-POSITIVE MYASTHENIA GRAVIS WITH RITUXIMAB

Arife Derda Yücel Şen, Ahmet Bayşal, Özlem Uğur Aydın, Kürşat Bora Çarman, Coşkun Yarar

Çocuk Dergisi - 2025;25(3):172-175

Eskisehir Osmangazi University Faculty of Medicine, Department of Pediatric Neurology, Eskisehir, Turkey

 

Muscle-specific tyrosine kinase antibody-associated myasthenia gravis (MuSK-MG) is a rare subtype of MG distinguished by recurring relapses and a clinical history unresponsive to conventional therapies. Rituximab, a monoclonal antibody that targets CD20+ B cells, has effectively induced long-term remission in adults. We report a pediatric MuSK-MG patient who exhibited a favorable response to rituximab following the ineffectiveness of steroid therapy and acetylcholinesterase inhibitor (AChEI) therapy. Keywords: Child * myasthenia gravis * MuSK